secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0000012208-25-000076
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26
----------------------------------------------------------------------------

- Revenue $653.0M, up slightly from $649.7M year-over-year.
- GAAP net loss $341.9M ($12.70 loss per diluted share) vs net income $653.2M in Q3 2024.
- Non-GAAP net income $60.8M ($2.26 per share) vs $56.3M ($2.02) in prior year.
- GAAP gross margin declined to 52.6% from 54.8%; non-GAAP gross margin declined to 53.5% from 55.6%.
- CEO cited disciplined cost management for better-than-expected operating margin despite funding headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000076/0000012208-25-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000076/bio-20251029.htm
  HTML page:      https://secwatch.observer/filing/0000012208-25-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer